



DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 JUNE 2021

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 6/30/2021 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 6/30/2020 RM'000	CURRENT YEAR TO DATE 6/30/2021 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 6/30/2020 RM'000
Revenue	155,439	143,331	321,893	302,044
Cost of Sales	(94,877)	(87,609)	(193,505)	(179,554)
Gross Profit	60,562	55,722	128,388	122,490
Other operating income	1,444	283	1,598	362
Distribution costs	(22,279)	(19,823)	(46,000)	(43,664)
Administration expenses	(17,153)	(14,987)	(36,297)	(34,676)
Other operating expenses	(109)	438	(669)	(3,820)
Profit from operations	22,465	21,633	47,020	40,692
Finance income	244	352	658	780
Finance costs	(2,512)	(2,594)	(4,305)	(4,354)
Profit before taxation	20,197	19,391	43,373	37,118
Taxation	(4,807)	(4,662)	(10,369)	(8,828)
Profit after tax for the period	15,390	14,729	33,004	28,290
Other comprehensive income				
Fair value of available-for-sale financial assets	40	11,871	(22,237)	10,422
Foreign currency translation differences for foreign operations	1,057	(75)	682	(895)
Total other comprehensive income for the period	16,487	26,525	11,449	37,817
Profit attributable to:				
Shareholders of the Company	15,390	14,729	33,004	28,290
Minority interest	-	-	-	-
	15,390	14,729	33,004	28,290
Total comprehensive income attributable to:				
Shareholders of the Company	16,487	26,525	11,449	37,817
Minority interest	-	-	-	-
	16,487	26,525	11,449	37,817
Earnings per share (sen)				
Basic (based on weighted average)	2.18	2.15	4.67	4.13
Diluted (based on weighted average)	2.18	2.15	4.67	4.13

- The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2020 and the accompanying explanatory notes attached to the interim financial statements.



DUOPHARMA

DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2021**

	AS AT 30/06/2021 RM'000	AS AT 31/12/2020 RM'000
ASSETS		
Property, Plant and Equipment	501,672	441,789
Investment property	1,100	1,100
Intangible assets	34,957	35,066
Other investments	92,079	112,247
Deferred Tax Assets	8,483	8,537
Total non-current assets	<u>638,291</u>	<u>598,739</u>
Inventories	184,903	151,266
Current Tax Assets	3,280	8,217
Trade & Other Receivables	161,253	142,181
Cash & Cash Equivalents	109,073	158,029
Total current assets	<u>458,509</u>	<u>459,693</u>
Total Assets	<u>1,096,800</u>	<u>1,058,432</u>
EQUITY		
Share Capital	405,857	404,922
Reserves	(2,838)	18,717
Retained earnings	210,824	220,182
Total Equity	<u>613,843</u>	<u>643,821</u>
LIABILITIES		
Borrowings	275,643	253,281
Trade & Other Payables	330	659
Deferred Tax Liability	10,558	10,350
Total non-current liabilities	<u>286,531</u>	<u>264,290</u>
Borrowings	65,451	48,793
Trade & Other Payables	127,207	100,784
Taxation	3,768	744
Total current liabilities	<u>196,426</u>	<u>150,321</u>
Total Liabilities	<u>482,957</u>	<u>414,611</u>
Total Equity & Liabilities	<u>1,096,800</u>	<u>1,058,432</u>
Net assets per share (RM)	0.87	0.91

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2020 and the accompanying explanatory notes attached to the interim financial statements.)



DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 JUNE 2021**

Group	<----- Non-distributable ----->			Distributable	
	Share Capital RM '000	Translation Reserve RM '000	Fair value Reserve RM '000	Retained Profit RM '000	Total RM '000
At 1 January 2021	404,922	(123)	18,840	220,182	643,821
Foreign currency translation differences for foreign operations	-	682	-	-	682
Net change in fair value of equity instrument designated at FVOCI	-	-	(22,237)	-	(22,237)
Profit for the year	-	-	-	33,004	33,004
Profit and total comprehensive income for the period	-	682	(22,237)	33,004	11,449
Issuance of 303,275 new shares pursuant to Dividend Reinvestment Plan	935	-	-	-	935
2020 Second Interim Dividend (6.0 sen)	-	-	-	(42,362)	(42,362)
At 30 June 2021	405,857	559	(3,397)	210,824	613,843



DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 JUNE 2021**

Group	←----- Non-distributable ----->			Distributable	Total RM '000
	Share Capital RM '000	Translation Reserve RM '000	Fair value Reserve RM '000	Retained Profit RM '000	
At 1 January 2020	374,404	273	(27,873)	182,946	529,750
Foreign currency translation differences for foreign operations	-	(396)	-	-	(396)
Net change in fair value of equity instrument designated at FVOCI	-	-	63,088	-	63,088
Transfer upon the disposal of equity investment designated at FVOCI	-	-	(16,375)	16,375	-
Profit for the year	-	-	-	58,610	58,610
Profit and total comprehensive income for the period	-	(396)	46,713	74,985	121,302
Issuance of 21,643,754 new shares pursuant to Dividend Reinvestment Plan	30,518	-	-	-	30,518
2019 Final Dividend (5.0 sen)	-	-	-	(34,219)	(34,219)
2020 Interim Dividend (0.5 sen)	-	-	-	(3,530)	(3,530)
At 31 December 2020	404,922	(123)	18,840	220,182	643,821

(The Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2020 and the accompanying explanatory notes attached to the interim financial statements.)



DUOPHARMA BIOTECH BERHAD
Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED CASH FLOW STATEMENT
FOR THE PERIOD ENDED 30 JUNE 2021

	30 June 2021	30 June 2020
	RM '000	RM '000
Cash flows from operating activities		
Profit before taxation	43,373	37,118
Adjustments for:		
Depreciation of property, plant and equipment	14,246	13,636
Amortisation of intangible asset	1,143	91
Finance income from		
- Cash and cash equivalents	(658)	(780)
Stock write off and / or impairment of inventories	5,345	2,076
Finance costs	4,305	4,354
Net impairment loss on trade receivables	95	195
Net unrealised foreign exchange loss	494	4,012
<i>Operating profit before changes in working capital</i>	<u>68,343</u>	<u>60,702</u>
Change in inventories	(38,982)	(6,865)
Change in receivables, deposits and prepayments	(19,167)	(18,819)
Change in payables and accruals	21,164	17,886
<i>Cash generated from operations</i>	<u>31,358</u>	<u>52,904</u>
Finance costs paid	(4,305)	(4,354)
Interest income	658	780
Income tax paid	(2,146)	(10,370)
Net cash generated from operating activities	<u>25,565</u>	<u>38,960</u>
Cash flows from investing activities		
Acquisition of other investment	(2,070)	(1,033)
Proceeds from disposal of investment	-	24,598
Acquisition of property, plant and equipment	(69,168)	(26,096)
Acquisition of intangible assets	(1,034)	(1,241)
Net cash used in investing activities	<u>(72,272)</u>	<u>(3,772)</u>
Cash flows from financing activities		
Drawdown of borrowings	46,649	29,947
Repayment of borrowings	(8,123)	(21,235)
Dividends paid to shareholders of the Company	(41,427)	-
Net cash used in financing activities	<u>(2,901)</u>	<u>8,712</u>
Net (decrease)/ increase in cash and cash equivalents	(49,608)	43,900
Exchange differences on translation of financial statement of foreign operations	682	(895)
Cash and cash equivalents at 1 January	158,029	120,669
Cash and cash equivalents as at 31 December	<u>109,103</u>	<u>163,674</u>
	-	-
(l) Cash and cash equivalents comprise:		
	<u>RM '000</u>	<u>RM '000</u>
Deposits placed with licensed banks	5,468	1,175
Cash and bank balances	86,400	131,872
Highly liquid investment with financial institutions	17,235	30,627
	<u>109,103</u>	<u>163,674</u>

(The Condensed Consolidated Cash Flow Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2020 and the accompanying explanatory notes attached to the interim financial statements.)



DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

(Incorporated in Malaysia)

Quarterly Report On Results For The Period Ended 30 June 2021

NOTES TO INTERIM FINANCIAL REPORT

A1 Accounting Policies and Method of Computation

The interim financial statements are unaudited and have been prepared in accordance with the applicable disclosure provisions of the Listing Requirements of the Bursa Malaysia Securities Berhad, MFRS 134: Interim Financial Reporting and with IAS 34, Interim Financial Reporting.

These interim financial statements should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2020 and the explanatory notes attached to the interim financial statements.

The following MFRSs and Amendments to MFRSs applicable to the Group have been adopted with effect from 1 January 2021 :

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2021

- Amendments to MFRS 9, Financial Instruments, MFRS 139, Financial Instruments: Recognition and Measurement, MFRS 7, Financial Instruments: Disclosures, MFRS 4, Insurance Contracts and MFRS 16, Leases – Interest Rate Benchmark Reform – Phase 2

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 April 2021

- Amendment to MFRS 16, Leases – Covid-19-Related Rent Concessions beyond 30 June 2021

The following are accounting standards, amendments and interpretations that have been issued by the Malaysian Accounting Standards Board (“MASB”) but have not been adopted by the Group:

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2022

- Amendments to MFRS 1, First-time Adoption of Malaysian Financial Reporting Standards (Annual Improvements to MFRS Standards 2018–2020)
- Amendments to MFRS 3, Business Combinations – Reference to the Conceptual Framework
- Amendments to MFRS 9, Financial Instruments (Annual Improvements to MFRS Standards 2018–2020)
- Amendments to Illustrative Examples accompanying MFRS 16, Leases (Annual Improvements to MFRS Standards 2018–2020)
- Amendments to MFRS 116, Property, Plant and Equipment – Proceeds before Intended Use
- Amendments to MFRS 137, Provisions, Contingent Liabilities and Contingent Assets – Onerous Contracts – Cost of Fulfilling a Contract
- Amendments to MFRS 141, Agriculture (Annual Improvements to MFRS Standards 2018–2020)

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2023

- MFRS 17, Insurance Contracts
- Amendments to MFRS 101, Presentation of Financial Statements – Classification of Liabilities as Current or Non-current and Disclosures of Accounting Policies
- Amendments to MFRS 108, Accounting Policies, Changes in Accounting Estimates and Errors – Definition of Accounting Estimates
- Amendments to MFRS 112, Income Taxes – Deferred Tax related to Assets and Liabilities arising from a Single Transaction

MFRSs, Interpretations and amendments effective for a date yet to be confirmed

- Amendments to MFRS 10, Consolidated Financial Statements and MFRS 128, Investments in Associates and Joint Ventures – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

The initial application of the above pronouncements did not have any material impact to the consolidated financial statements of the Group.

A2 Audit Report

The audited report of the Company's preceding annual financial statements was not qualified.

A3 Seasonal or Cyclical Factors

The Group's sales typically peak in the first three quarters of the calendar year with higher demand in the public health sector and will gradually taper off in the final quarter of the calendar year.

A4 Exceptional/Extraordinary Items

There were no exceptional/extraordinary items for the financial period under review.

A5 Changes in Estimates

There was no change in estimates that have a material effect in the current quarter results.

A6 Debts and Equity Securities

During the current financial quarter, 303,275 new ordinary shares of Duopharma Biotech were issued in relation to the Dividend Reinvestment Plan (DRP) exercise undertaken by the Company. The said shares were listed and quoted on the Main Market of Bursa Malaysia Securities Bhd on 24 May 2021.

A7 Dividend Paid

The Group paid a second interim dividend of 6 sen per share (2020: a final dividend of 5 sen per share) equivalent to RM 42.36 million (2020: RM 34.22 million) in respect of financial year ended 31 December 2020 during the current quarter.

Out of the total cash distribution, a total of RM 0.93 mil was converted into 303,275 new ordinary shares of the Company at the conversion price of RM 3.08 per ordinary share under the Dividend Reinvestment Plan.

A8 Segment Information

	Quarter Ended		Year To Date	
	6/30/2021		6/30/2021	
	RM ' 000		RM ' 000	
Sales by operating sector :-	Sales	Gross Profit	Sales	Gross Profit
Local	144,919	56,244	300,401	120,756
Export	10,520	4,318	21,492	7,632
	155,439	60,562	321,893	128,388

A9 Post Balance Sheet Events

Subsequent to Balance Sheet date, the shareholders of the Company have approved the Proposed Bonus Issue at a Meeting of Members on 13 August 2021.

Further details are disclosed in Note B7 below.

A10 Changes in the Composition of the Group

There were no changes in the composition of the Group during the current quarter.

ADDITIONAL INFORMATION REQUIRED BY BURSA SECURITIES LISTING REQUIREMENTS

B1 Review of Performance

	Year To Date (30/06/21) RM'000	Year To Date (30/06/20) RM'000	Variance	
			RM'000	%
Revenue	321,893	302,044	19,849	6.57
Profit before tax (PBT)	43,373	37,118	6,255	16.85
Profit after tax (PAT)	33,004	28,290	4,714	16.66

The Group recorded a revenue and PBT of RM321.9 million and RM44.2 million respectively for current period ended 30 June 2021 as compared to RM302.0 million and RM37.1 million for the corresponding period last year. The Group's revenue has improved as compared to last year corresponding period mainly due to higher sales to the consumer healthcare and public health sector during the period. The Group's PBT also improved as compared to last year corresponding period mainly due to the increase in sales during the quarter and forex loss in last year corresponding period.

B2 Comparison with the Preceding Quarter's Results

	Qtr 2 2021 (30/06/21) RM'000	Qtr 1 2021 (31/03/21) RM'000	Variance	
			RM'000	%
Revenue	155,439	166,454	(11,015)	(6.62)
Profit before tax (PBT)	20,197	23,176	(2,979)	(12.85)
Profit after tax (PAT)	15,390	17,614	(2,224)	(12.63)

The Group's revenue decreased to RM155.4 million for current quarter ended 30 June 2021 as compared to RM166.5 million in the preceding quarter mainly due to a lower demand from public health sector and ethical specialty business. Decrease in sales has led to lower PBT which decreased from RM23.2 million in preceding quarter to RM20.2 million in current quarter ended 30 June 2021.

B3 Prospects for the Remainder of Current Financial Year

Malaysia's GDP increased 16.1 per cent in the second quarter of 2021 (1Q 2021: -0.5%). However, the strong growth for this quarter was also attributed to the low base recorded in the second quarter of 2020. The baseline projection has been revised from 6.0 – 7.5% previously to 3.0 – 4.0% in 2021 due mainly to the impact of the containment measures. However, Malaysia's growth is expected to remain on a recovery path, supported by stronger external demand, faster progress in vaccination rate and the continued targeted policy support for households and businesses.

The World Bank has also revised their GDP growth projection for Malaysia for the second time to 4.5% in 2021 — from 6% estimated in March and 6.7% in December 2020 — taking into account a flare-up in Covid-19 infections and slower-than-expected vaccine rollout.

The pandemic has caused huge uncertainties in the business environment. Consumers are more cautious in their spending. The outbreak has also resulted in disruption in global supply chain as many countries have also closed their borders which inadvertently heighten challenges to conduct business activities, which have dampened the global economic outlook.

The budget 2021 has seen an increase of 4.2% in allocation for healthcare sector to RM 31.9 billion, the highest allocation in the history. In addition, the following developments augur well for the business of Duopharma:

a) the contract period of the Agreement for the Supply and Delivery of Human Insulin Products under the Government of Malaysia has been extended by one (1) year effective from 2 December 2020 until 1 December 2021 with an additional contract value of RM19,625,100.

b) the contract period of the Supply Agreements for the supply of pharmaceutical and/or non-pharmaceutical products to hospitals, clinics and others under the Government of Malaysia have been extended for twenty five (25) months, commencing 1 December 2019 until 31 December 2021.

The extensions augur well for the Group as it stabilises significant portion of the Group's revenue for the said period and enables the Group to mobilise our resources to intensify its foray into the specialty products as one of its strategies moving forward to create a pool of niche products.

c) Duopharma (M) Sendirian Berhad ("DMSB"), a wholly-owned subsidiary of the Company, had on 26 January 2021 entered into a term sheet with the Government of Malaysia (the "Government Term Sheet") to supply 6.4 million doses of the "Sputnik V" adenovirus vector vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology (the "Institute") for SARS-Cov-2 (COVID-19) (the "Vaccine"). DMSB had also signed a term sheet with the Joint-Stock Company "Management Company of Russian Direct Investment Fund" ("RDIF") to secure the 6.4 million doses of the Vaccine (the "RDIF Term Sheet"). RDIF is the appointed marketing agent for Gamaleya for all international markets.

In furtherance of the RDIF Term Sheet, RDIF had nominated and authorised a subsidiary of RDIF (the "Seller"), to enter into the supply agreement with DMSB to perform the obligations for the supply of the Vaccine to DMSB as envisaged under the RDIF Term Sheet. DMSB has executed a supply agreement dated 12 May 2021 with the Seller (the "Seller Supply Agreement") for the supply to DMSB of the finished form of the Vaccine in the Territory upon the terms and conditions therein contained.

Pursuant to the Government Term Sheet, DMSB had entered into a supply agreement dated 25 May 2021 with the Government of Malaysia (the "Government Supply Agreement") for the supply by DMSB to the Government of the finished form of the Vaccine upon the terms and conditions therein contained.

The supply of the Vaccine under the Seller Supply Agreement and the Government Supply Agreement is respectively subject to the condition precedent requiring the approval of the Vaccine by the Drug Control Authority, Malaysia ("DCA"). All efforts have been put in place in order to expedite the approval process.

d) DCA has recently granted to DMSB the conditional registration for emergency use for the COVIL0 Suspension for Injection COVID-19 Vaccine (Vero Cell), Inactivated ("Covid-19 Sinopharm Vaccine") developed by China National Biotec Group Company Limited.

The management of vaccine supply is expected to contribute positively to the future earnings of Duopharma Biotech Group for the financial year ending 31 December 2021.

Barring any unforeseen circumstances, Duopharma Biotech Group is expected to achieve satisfactory results in FY 2021.

B4 Profit Forecast

No commentary is made on any variance between actual profit from forecast profit as it does not apply to the Group.

B5 Taxation

Details of taxation are as follows :-

	Current Year Quarter 30/06/21 RM'000	Current Year To Date 30/06/21 RM'000
Based on results for the quarter/year	(4,623)	(10,107)
Transfer to deferred tax	(184)	(262)
	(4,807)	(10,369)

The Group's tax expense is recognised in each financial quarter based on the best estimate of the expected annual income tax rate for the full financial year.

B6 Unquoted Investments and Properties

There was no disposal of unquoted investment and/or properties during the current financial quarter.

B7 Status of corporate proposals

a) On 22 February 2021, the Board of Directors had resolved that the Dividend Reinvestment Plan ("DRP") approved by the shareholders at the Company's Extraordinary General Meeting held on 31 May 2018 would apply to the Second Interim Dividend of 6.0 sen per share amounting to approximately RM42.36 million. The issue price of the new ordinary shares in the Company issued pursuant to the DRP was fixed at RM 3.08 per new Duopharma Biotech Berhad share. The issue price was at a discount of approximately 10% to the 5-day ex-dividend volume weighted average market price (VWAMP) of RM 3.42.

A total of 303,275 new shares have been issued and allotted pursuant to the Dividend Reinvestment Plan. The aforesaid new Duopharma Biotech Shares were listed and quoted on the Main Market of Bursa Malaysia Securities Berhad with effect from 24 May 2021.

b) On 3 May 2021, the Board of Directors had resolved to approve the proposed bonus issue by the Company of up to 239,926,896 new ordinary shares in Duopharma Biotech Berhad ("Duopharma Shares") ("Bonus Shares") on the basis of 1 Bonus Share for every 3 existing Duopharma Shares held ("Proposed Bonus Issue").

Following the additional listing application that was submitted to Bursa Securities Malaysia Berhad ("Bursa Securities") by the Company after the listing and quotation of the aforesaid 303,275 new Duopharma Shares that were issued and allotted pursuant to the Dividend Reinvestment Plan, Bursa Securities had on 15 June 2021 resolved to approve the listing and quotation of 235,443,397 new ordinary shares to be issued pursuant to the Proposed Bonus Issue.

The Proposed Bonus Issue was subsequently approved by the shareholders of the Company at a Meeting of Members on 13 August 2021.

The entitlement date of the Bonus Shares will be determined and announced later.

B8 Borrowings and Debt Securities

Details of Group's borrowings are as follows :-

	As at 30 June 2021 RM'000	As at 31 December 2020 RM'000
Current - unsecured	65,451	48,793
Non-current - unsecured	275,643	253,281
Total	341,094	302,074

B9 Material litigation

There was no material litigation up to 17 August 2021.

B10 Dividend

For the current financial period ended 30 June 2021, the Board of Directors has resolved that an interim dividend of 0.5 sen per share be paid by the Company based on paid up capital of 706,330,193 shares amounting to approximately RM 3.532 million (2020 : interim dividend of 0.5 sen per share based on paid up capital of 706,026,918 shares amounting to RM 3.530 million). The entitlement date and the payment date will be 1 September 2021 and 15 September 2021 respectively.

The Board of Directors has also resolved that the Dividend Reinvestment Plan shall not apply to the aforesaid interim dividend.

B11 Earnings per Share

	Current year quarter 30/06/21	Current year to date 30/06/21
a) Basic EPS		
Net profit (RM'000)	15,390	33,004
Weighted average number of ordinary shares in issue ('000)		
- Balance b/f	706,027	706,027
-Weighted average number of shares arising from Effect of Dividend Reinvestment Plan	123	31
	706,150	706,058
Basic EPS (sen)	2.18	4.67
b) Dilutive EPS		
Adjusted weighted average number of ordinary shares in issue ('000)		
-In issue during the period	706,150	706,058
	706,150	706,058
Dilutive EPS (sen)	2.18	4.67

B12 Profit Before Tax

	Current year quarter 30/06/21 RM '000	Current year to date 30/06/21 RM '000
Operating profit is arrived at after charging / (crediting):		
Depreciation of property, plant and equipment	7,093	14,246
Finance costs	2,512	4,305
Stock write off and/or impairment of inventories	4,973	5,345
Net foreign exchange loss / (gain)	124	977
Interest income	244	658

Other than the above, there were no impairment of assets and gain or loss on derivatives for the current quarter and current period ended 30 June 2021.

B13 Authorisation for issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the directors on 17 August 2021.

By Order of the Board

Ibrahim Hussin Salleh
Secretary
License No.: LS 0009121
SSM Practising Certificate No.: 201908001032
Kuala Lumpur
17 August 2021